SEC Form 4 · accession 0001209191-16-103573
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Byrnes
Director
Period of report
Feb 24, 2016
Accepted (ET)
Feb 29, 2016 · 8:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 24, 2016 | G | 10,999 | $0.00 | D | 0 | D | |
| Common StockF1 | Feb 24, 2016 | G | 10,999 | $0.00 | A | 13,665 | I | By The Byrnes Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents transfer of shares to the Mr. Byrnes' Family Trust. Mr. Byrnes continues to beneficially own such shares through indirect ownership through The Byrnes Family Trust.